Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

Core Viewpoint - Wave Life Sciences Ltd. is set to host a live webcast and conference call on March 4, 2025, to discuss its fourth quarter and full year 2024 financial results and provide business updates [1]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [4]. - The company's RNA medicines platform, PRISM, integrates various modalities, chemistry innovations, and insights from human genetics to achieve scientific breakthroughs for treating both rare and common disorders [4]. - Wave's RNA-targeting modalities include editing, splicing, RNA interference, and antisense silencing, which enhance its capabilities in designing and delivering therapeutic candidates [4]. - The company's diversified pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [4]. - Wave Life Sciences is driven by the mission to "Reimagine Possible," aiming to alleviate the burden of disease on human potential [4].